Aparna Parikh Chloe Atreya W Michael Korn Alan P Venook
10.6004/jnccn.2017.0002
J Natl Compr Canc Netw
2017 Jan;15(1):3-8.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/28040715/
Antineoplastic Agents / therapeutic use Colorectal Neoplasms / therapy Liver Neoplasms / therapy Molecular Targeted Therapy / methods Receptor, ErbB-2 / genetics
Antineoplastic Agents / therapeutic use Colorectal Neoplasms / therapy Liver Neoplasms / therapy Molecular Targeted Therapy / methods Receptor, ErbB-2 / genetics Case Reports Ado-Trastuzumab Emtansine Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biopsy Camptothecin / administration & dosage Camptothecin / analogs & derivatives Camptothecin / therapeutic use Chemoradiotherapy, Adjuvant Colorectal Neoplasms / diagnosis Colorectal Neoplasms / genetics Colorectal Neoplasms / pathology DNA Mutational Analysis / methods Disease Progression Drug Resistance, Neoplasm Fluorouracil / administration & dosage Fluorouracil / therapeutic use Gene Amplification High-Throughput Nucleotide Sequencing Humans Laparoscopy Leucovorin / administration & dosage Leucovorin / therapeutic use Liver Neoplasms / genetics Liver Neoplasms / pathology Liver Neoplasms / secondary Male Maytansine / administration & dosage Maytansine / analogs & derivatives Maytansine / therapeutic use Middle Aged Off-Label Use Palliative Care / methods Proto-Oncogene Proteins c-myc / genetics Tomography, X-Ray Computed Trastuzumab Tumor Suppressor Protein p53 / genetics Ultrasonography Antibodies, Monoclonal, Humanized Antineoplastic Agents MYC protein, human Proto-Oncogene Proteins c-myc TP53 protein, human Tumor Suppressor Protein p53 Maytansine Receptor, ErbB-2 Trastuzumab Leucovorin Ado-Trastuzumab Emtansine Fluorouracil Camptothecin IFL protocol
PMC5564419
28040715
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
2017